DWA
SPRO icon

Dorsey Wright & Associates’s Spero Therapeutics SPRO Stock Holding History

Dorsey Wright & Associates’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-850
Closed -$11K – 356
2020
Q2 		$11K Buy
+850
New +$9.54K ﹤0.01% 227

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Dorsey Wright & Associates's SPRO Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of Spero Therapeutics (SPRO) in Q3 2020, closing a stake of 850 shares — an estimated $11K sold.

Dorsey Wright & Associates first reported a position in SPRO in Q2 2020 and held it in 1 quarter. The position peaked at $11K in Q2 2020. 78 funds tracked by Wall St. Rank hold SPRO as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining Spero Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 850 Spero Therapeutics shares in Q3 2020, an estimated $11K.
  • Dorsey Wright & Associates first reported a position in Spero Therapeutics in Q2 2020 and held it in 1 quarter.
  • Dorsey Wright & Associates's Spero Therapeutics position peaked at $11K in Q2 2020.
  • 78 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.